Why do we continue to overtreat stage Ia carcinoma of the cervix?

American Journal of Obstetrics and Gynecology
Tommy BuchananWilliam T Creasman

Abstract

The current recommended treatment for stage Ia2 cervical cancer is a radical or modified radical hysterectomy. Although in the United States the incidence of cervical cancer is low and declining, almost 50% of the >4000 new cases will present in early stages. An estimated 2200 women each year will undergo radical hysterectomy and many will have both early- and late-onset complications. The purpose of this review is to examine if there is still a role for radical hysterectomy in the proper treatment of stage Ia2 cervical cancer given most recent data. Sufficient histological evidence suggests that although parametrial involvement and lymph node metastases can increase the risk for recurrence, they are relatively uncommon at early stages. Worldwide data that challenge radical hysterectomy as standard of care have shown that conservative management of stage Ia2 cervical cancer results in similar survival and recurrence rates. It is the recommendation based on all reviewed data that radical hysterectomy should no longer be considered standard of care in all cases of stage Ia2 cervical cancer.

References

Jul 1, 1993·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·A G Ostör
Jun 1, 1996·Obstetrics and Gynecology·J L Benedet, G H Anderson
Oct 1, 1996·Gynecologic Oncology·S L BuckleyJ R van Nagell
Feb 18, 1998·American Journal of Obstetrics and Gynecology·W T CreasmanH D Homesley
May 6, 1999·The New England Journal of Medicine·K BergmarkG Steineck
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P. ElliottM. Jones
Oct 9, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J-H NamJ-E Mok
Dec 25, 2003·Critical Reviews in Oncology/hematology·Marzio Angelo ZulloPierluigi Benedetti Panici
Jan 10, 2004·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Mary RyanPatricia Mackenzie
Feb 10, 2004·Gynecologic Oncology·William T Creasman, Matthew F Kohler
Jun 29, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K B M LeeS Y Ha
Jan 13, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Shanti Kankipati RajuOmer Devaja
Nov 3, 2012·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A AchouriF Lécuru
May 3, 2013·Obstetrics and Gynecology·Daniel L Clarke-Pearson, Elizabeth J Geller
Jul 19, 2013·Gynecologic Oncology·Clare J ReadeAllan Covens
Mar 6, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Juliana Yoko YonedaLuiz Carlos Zeferino
May 15, 2015·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·B-G XieW-J Zhu
Nov 14, 2015·Journal of Cancer Survivorship : Research and Practice·Åsa H EverhovKarin E Smedby
Jan 24, 2016·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Selcuk SelcukAtes Karateke

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.